ISRCTN55678797已完成不适用
Acute Myeloid Leukaemia (AML) Trial 12 (modified) for patients aged under 60
Medical Research Council (MRC) (UK)0 个研究点目标入组 500 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Have one of the forms of AML
- •2. Are considered suitable for intensive chemotherapy
- •3. Are normally under the age of 60 years, but can be older as long as intensive therapy is considered suitable
- •4. Have given written informed consent
排除标准
- •Added as of 07/03/2007:
- •1. Previously received any treatment for APL
- •2. Other forms of AML (including CML in promyelocytic blast crisis)
- •3. Another concurrent active malignancy
- •4. Pregnant or consider the possibility of becoming pregnant during the course of treatment
研究者
相似试验
已完成
不适用
Acute myeloid leukaemia (AML) trial 12 (protocol for children)eukaemiaLeukaemiaCancerISRCTN64649191Medical Research Council (MRC) (UK)2,000
已完成
不适用
Acute lymphoblastic leukaemia (ALL) trial XII (joint trial with Eastern Co-operative Oncology Group - E2993)eukaemiaCancerLeukaemiaISRCTN77346223Medical Research Council (MRC) (UK)550
已完成
不适用
AML 12 - Acute myeloid leukaemia Adults (modified)CancerISRCTN17833622Medical Research Council (MRC) (UK)
已完成
不适用
KALL R2 - Acute Lymphoblastic Leukaemia trialAcute Lymphoblastic LeukaemiaCancerISRCTN95257778Medical Research Council (MRC) (UK)200
招募中
2 期
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).Acute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12619000280101Australian Leukaemia and Lymphoma Group (ALLG)75